A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...

CART, a next-gen CAR-T therapy for improved targeting and functionality to address this. “ALA-CART improves the ability of ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

Researchers uncover how leukemia drains T cells' energy, paving the way for stronger cancer immunotherapy and enhancing CAR T ...

Discover how the ALA-CART platform enhances CAR T cell efficacy against antigen-low leukemias. With improved LAT activation, ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...